To evaluate the efficacy and safety of Duliang soft capsule in chronic daily headache: a clinical study through randomised, double-blind, multicenter and placebo-controlled

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003459

Enrollment

Unknown

Registered

2013-08-14

Start date

2012-12-31

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic daily headache

Interventions

treatment group:Duliang soft capsule

control group:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: According to the CDH diagnostic standard, the duration of heach more than 3 months and each month more than 15 days; Aged 18-65 yearsSigned the informed consent.

Exclusion criteria

Exclusion criteria: (1) the secondary headache in addition to MOH; (2) complicated with cardiovascular, liver, kidney, brain, endocrine system and blood system, severe primary disease, malignant tumor, psychosis, epilepsy, glaucoma patients; (3) treatment with otherexperimental drugs within two weeks ,such as antidepressant, anxiety, seizures, Ca2+ antagonists, beta blockers, headache medicine and taking part in other clinical trials; (4) history of illicit drugs during the previous year; (5) Female who is pregnant, lactating or ready to pregnant.

Design outcomes

Primary

Measure	Time frame
Headache-free rate;	—

Secondary

Measure	Time frame
Painkillers drug consumption;Duration of headach;nausea;vomiting;photophobia;dizzy;Quality of life;Pain symptoms scores;phonophobia;headach day;	—

Countries

China

Contacts

Public ContactYu Shengyuan

yusy1963@126.com+86 13501171068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026